Abstract
Chemoimmunotherapy (CIT) such as FCR (fludarabine, cyclophosphamide, rituximab) has been the standard first-line therapy for younger patients with CLL. In the last few years, several novel targeted therapies have been developed for patients with CLL. These include B-cell receptor (BCR) inhibitors such as Bruton tyrosine kinase (BTK) inhibitors, PI3 kinase inhibitors, and Syk inhibitors, novel anti-CD20 monoclonal antibodies such as ofatumumab and obinutuzumab, and Bcl-2 antagonists such as venetoclax (ABT-199). Strategies targeting the immune system such as lenalidomide, chimeric antigen receptor (CAR) T cells, and more recently, checkpoint inhibitors, are in clinical development. Ibrutinib and idelalisib are already approved for patients with relapsed and refractory CLL. Ibrutinib is also approved for first-line treatment of CLL patients with del(17p). Several ongoing phase III clinical trials with novel therapies will further define the role of targeted agents in CLL.
Original language | English (US) |
---|---|
Pages (from-to) | 233-244 |
Number of pages | 12 |
Journal | Blood Reviews |
Volume | 30 |
Issue number | 3 |
DOIs | |
State | Published - May 1 2016 |
Keywords
- Chronic lymphocytic leukemia
- Ibrutinib
- Idelalisib
- Obinutuzumab
- Targeted therapy
ASJC Scopus subject areas
- Hematology
- Oncology